Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant loss of -62.75% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -3.39%. Over the past 30 days, the price of GTBP has leaped by -5.32%. And in the last five days, it has surged by 13.55%.
GT Biopharma Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $10.66 on 05/20/24 and the lowest value was $1.72 on 12/20/24.
52-week price history of GTBP Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. GT Biopharma Inc’s current trading price is -73.26% away from its 52-week high, while its distance from the 52-week low is 65.70%. The stock’s price range during this period has varied between$1.72 and $10.66. The GT Biopharma Inc’s shares, which operate in the Healthcare, saw a trading volume of around 18.8 million for the day, a figure considerably higher than their average daily volume of 25180.0 over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
GT Biopharma Inc (GTBP) has experienced a quarterly rise of 42.50% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.79M and boasts a workforce of 2 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.4688, with a change in price of +0.3298. Similarly, GT Biopharma Inc recorded 206,199 in trading volume during the last 100 days, posting a change of +12.93%.
GTBP’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for GTBP stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
GTBP Stock Stochastic Average
As of today, GT Biopharma Inc’s raw stochastic average for the last 50 days stands at 48.73%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 48.73%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 18.04% and 9.98%, respectively.
